Yom Chai Forms Strategic Partnership With Israeli Research and Development Company Kaneh-B

Partnership Will Conduct Scientific Clinical Trials On ADHD; Distribute Approved European Dermal Products

ISRAEL:  Yom Chai has entered into a strategic partnership with Kaneh-B to co-found the development and clinical validation of a range of cannabis based ADHD products.

yom chaiYom Chai’s objective is to conduct scientific trials in Israel utilizing various Cannabinoid and Terpene profiles with the goal of realizing multiple successful discoveries (outcomes). Yom Chai’s goal is to bridge the gap between patients and doctors to bring scientifically validated products to market.

Scot Albert, COO of Yom Chai said, “We are excited to be working with Ofer Segal CEO and Yahav Blaicher Co-Founder of Kaneh-B to formulate, manufacture, and distribute world class Cannabis based products to the international marketplace.”

Yom Chai Signs MOU With Way Of Life Medical Cannabis For Israel, Portugal And Malta.

ISRAEL: New medical cannabis company Yom Chai has entered into a Memorandum of Understanding (“MOU”) with Way of Life Medical Cannabis to breed proprietary genetics, formulate, manufacture and distribute a wide range of Cannabis-based products to treat various medical conditions.

Way Of Life

Yom Chai’s objective is to conduct scientific trials in Israel utilizing various Cannabinoid and Terpene profiles with the goal of realizing multiple successful discoveries (outcomes). Yom Chai’s goal is to bridge the gap between patients and doctors to bring scientifically proven products to market.

Scot Albert, COO of Yom Chai said, “We are excited to be working with Way of Life Medical Cannabis and Iris Vermouth, CEO to formulate, manufacture, and distribute world-class Cannabis based products to the international marketplace”.

Way of Life Medical Cannabis holds a license in Israel to cultivate Medical cannabis on Moshav Aviel and is a cooperative agricultural community of individual farms in the “Israel Toscana” area. 

iCAN Signs MoU With Yom Chai for Crohn’s Disease And Autism

ISRAEL: The Directors of Ananda Developments have announced that investee company iCAN has signed an MoU with a new Israeli Medical Cannabis company Yom Chai to develop and clinically validate cannabis based treatments for Crohn’s Disease, Autism and other neurodevelopmental, neurodegenerative and gastrointestinal diseases.

iCANN logo finalYom Chai has deep experience in the international medical cannabis market opening and running dispensaries and production facilities as well as providing consulting services to a wide range of cannabis businesses.

Yom Chai, in collaboration with leading American and Israeli scientists and medical professionals is initially developing a formulated suppository targeting people suffering from Crohn’s Disease and will develop various targeted cannabis formulations including treatment for children and adults with Autism.

iCAN will be supporting Yom Chai by combining its unique access to innovation and technology with unmatched industry insights and international connections. The signing of this MoU provides iCAN with a combination of revenue, equity and future royalties.